News / Spectrum

BCL11A-related intellectual developmental disorder; intervention dosage; gray-matter volume

Here is a roundup of autism-related news and research spotted around the web for the week of 11 November.

By Jill Adams
12 November 2024 | 2 min read
comments
https://doi.org/10.53053/LWRF1005 https://doi.org/10.53053/LWRF1005 - opens a new tab Cite this article
  • Genotype-phenotype analysis of 77 people with BCL11A-related intellectual developmental disorder shows a range of BCL11A variants and traits, including microcephaly, hypotonia, persistence of fetal hemoglobin and autism. European Journal of Human Genetics
  • A clinical trial of the metabotropic glutamate receptor 5 modulator known as mavoglurant found no change in the levels of blood biomarkers in people with fragile X syndrome. SAGE Open Medicine
  • People with de novo variants of the GSK3B gene, which affect neuron morphology, tend to have developmental delay, sleep problems, aggression and autism, according to a study in 15 people. Molecular Psychiatry
Size matters: A new atlas shows decreases (green) and increases (yellow) in gray-matter volume in autism (bottom row) and attention-deficit/hyperactivity disorder (top row).
  • In a letter, Thomas Frazier and his colleagues argue that biased sampling led to an errant conclusion about intervention dosage for people with autism. In a reply, Micheal Sandbank and a co-author assert that Frazier’s pooling of data across interventions is misleading. Spectrum has previously reported on Sandbank’s concern about negative findings that aren’t published despite preregistration. JAMA Pediatrics
  • Specific changes in regional gray-matter volume that align with psychiatric diagnoses can be gleaned by taking co-occurring conditions into account. Biological Psychiatry
  • A phosphodiesterase 4D inhibitor called BPN14770, which improves cognitive function in men with fragile X syndrome, alters N1 event-related potentials in a blood-level-dependent way, suggesting that EEG can produce a treatment biomarker. Spectrum covered the earlier clinical trial results of this drug in 2021. Molecular Autism
  • The editors of PLOS ONE have retracted a 2020 article that purported to identify a predictive profile for autism based in part on nine biomarkers. Concerns included irregularity in the raw data files. PLOS ONE

Sign up for the weekly Spectrum newsletter.

Stay current with the latest advancements in autism research.

Recommended reading

Illustration of a child asleep with brainwave-like lines superimposed above them.
Spectrum

Exploring the connection between autism and sleep

By Daisy Yuhas
7 November 2024 | 2 min read
Illustration of an open journal featuring lines of text and small illustrations of eyes and mouths.
Spectrum

Sleep; noncoding regions of the genome; changing rates of U.S.-based autism diagnoses

By Jill Adams
5 November 2024 | 2 min read
Research image of human brain scans against a black background.
Spectrum

Cerebellum structure; AMPA receptors; MAGEL2 gene

By Jill Adams
29 October 2024 | 1 min read

Explore more from The Transmitter

Neuroscience

Happy 1st Birthday, The Transmitter!

By Ivan Oransky
13 November 2024 | 2 min read
Illustration of a brain overlaid with circles containing flowers and circuit-like networks, among other images.
NeuroAI

NeuroAI: A field born from the symbiosis between neuroscience, AI

By Anthony Zador
11 November 2024 | 6 min read
Illustration of a simple matrix of overlapping circles next to a more complex network of intersecting lines against a muted but colorful background.
NeuroAI

What the brain can teach artificial neural networks

By Anthony Zador
11 November 2024 | 7 min read